Moderna — Shares tumbled 10% after the pharma giant said the Food and Drug Administration refused to review its application ...

The rise of gene editing forces regulators to confront a difficult question: How to protect fair play in the age of genomic medicine.

Acadia Healthcare — The health-care stock popped 10% after investor David Einhorn told CNBC that he has been buying the stock. The Greenlight Capital fund manager said he's hopeful the company's new ...

US stocks rallied on Wednesday as traders cheered a stronger-than-expected jobs report. The S&P 500 Index advanced 0.4% at 9.57am in New York, with the gauge headed for an all-time high.

Ever since 6-year-old Emily Whitehead became the first pediatric patient to receive CAR-T cell therapy in 2012, when T cells ...

TASR brings a quick morning overview of the most important events seen in Slovakia on the previous day (Wednesday, 11 February): STRASBOURG - The European Commission (EC) considers the adoption of the ...

America’s drug safety agency declined to review a next-gen flu vaccine that uses the same tech as the coronavirus shots ...

After the FDA’s decision to reject a review of Moderna’s mRNA-1010 flu shot, executives explain what Americans will miss out ...

The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday ...

The Food and Drug Administration is refusing to consider Moderna's application for a new flu vaccine made with mRNA technology, the company said.

The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with mRNA ...

The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said Tuesday, in another setback for the technology ...